 Jonathan Shortt
Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schistosoma japonicum | 2 | 2021 | 34 | 1.140 |
Why?
| | Schistosomiasis japonica | 2 | 2021 | 35 | 0.770 |
Why?
| | Genetic Variation | 4 | 2024 | 972 | 0.680 |
Why?
| | Metagenomics | 1 | 2021 | 149 | 0.610 |
Why?
| | Selection, Genetic | 2 | 2021 | 261 | 0.600 |
Why?
| | Microsatellite Repeats | 2 | 2018 | 157 | 0.600 |
Why?
| | Pre-Eclampsia | 3 | 2025 | 206 | 0.530 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 530 | 0.390 |
Why?
| | Placenta | 3 | 2025 | 786 | 0.390 |
Why?
| | Biological Specimen Banks | 4 | 2026 | 109 | 0.360 |
Why?
| | Genotype | 4 | 2026 | 1852 | 0.350 |
Why?
| | Polymorphism, Single Nucleotide | 6 | 2026 | 2158 | 0.350 |
Why?
| | Receptors, KIR | 3 | 2022 | 118 | 0.330 |
Why?
| | Thyroid Neoplasms | 2 | 2026 | 350 | 0.320 |
Why?
| | China | 3 | 2021 | 270 | 0.310 |
Why?
| | Genome-Wide Association Study | 4 | 2026 | 1407 | 0.240 |
Why?
| | Thyroid Diseases | 1 | 2026 | 44 | 0.230 |
Why?
| | Precision Medicine | 3 | 2024 | 459 | 0.220 |
Why?
| | Prealbumin | 1 | 2024 | 37 | 0.210 |
Why?
| | Amyloid Neuropathies, Familial | 1 | 2024 | 26 | 0.210 |
Why?
| | Multifactorial Inheritance | 1 | 2025 | 195 | 0.200 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2025 | 134 | 0.200 |
Why?
| | Pharmacogenetics | 2 | 2025 | 175 | 0.200 |
Why?
| | Thyroid Nodule | 1 | 2024 | 57 | 0.190 |
Why?
| | Fatty Acids | 1 | 2025 | 457 | 0.180 |
Why?
| | Receptors, KIR3DS1 | 1 | 2022 | 7 | 0.180 |
Why?
| | Receptors, KIR3DL1 | 1 | 2022 | 20 | 0.180 |
Why?
| | Genetic Predisposition to Disease | 3 | 2025 | 2378 | 0.180 |
Why?
| | Collagen Type VII | 1 | 2021 | 27 | 0.170 |
Why?
| | Jews | 1 | 2021 | 20 | 0.170 |
Why?
| | Epidermolysis Bullosa Dystrophica | 1 | 2021 | 41 | 0.170 |
Why?
| | Genes, MHC Class I | 1 | 2021 | 37 | 0.170 |
Why?
| | Desogestrel | 1 | 2021 | 46 | 0.160 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2021 | 88 | 0.160 |
Why?
| | Killer Cells, Natural | 2 | 2021 | 480 | 0.160 |
Why?
| | Evolution, Molecular | 2 | 2021 | 492 | 0.150 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2025 | 2588 | 0.150 |
Why?
| | Software | 1 | 2024 | 680 | 0.140 |
Why?
| | Snakes | 1 | 2018 | 19 | 0.140 |
Why?
| | Lizards | 1 | 2018 | 43 | 0.140 |
Why?
| | Phenotype | 5 | 2025 | 3155 | 0.130 |
Why?
| | Primates | 1 | 2019 | 133 | 0.130 |
Why?
| | Heterozygote | 1 | 2019 | 313 | 0.130 |
Why?
| | Genotyping Techniques | 1 | 2017 | 71 | 0.120 |
Why?
| | Humans | 21 | 2026 | 145474 | 0.120 |
Why?
| | Patient Acceptance of Health Care | 1 | 2023 | 881 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2023 | 946 | 0.120 |
Why?
| | Genetics, Population | 1 | 2017 | 217 | 0.110 |
Why?
| | Genome | 1 | 2017 | 305 | 0.100 |
Why?
| | Phylogeny | 1 | 2018 | 917 | 0.100 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 777 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2025 | 2214 | 0.100 |
Why?
| | Colorado | 4 | 2024 | 4553 | 0.100 |
Why?
| | Genomics | 3 | 2024 | 825 | 0.090 |
Why?
| | Female | 11 | 2025 | 78844 | 0.090 |
Why?
| | HLA-B Antigens | 2 | 2022 | 58 | 0.090 |
Why?
| | Pilot Projects | 1 | 2017 | 1891 | 0.080 |
Why?
| | Altitude | 2 | 2025 | 463 | 0.080 |
Why?
| | Animals | 4 | 2021 | 38030 | 0.080 |
Why?
| | Neoplasms | 1 | 2025 | 2906 | 0.070 |
Why?
| | Aged | 6 | 2025 | 26153 | 0.070 |
Why?
| | Fetal Growth Retardation | 2 | 2025 | 593 | 0.070 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 2187 | 0.070 |
Why?
| | Pregnancy | 3 | 2025 | 7202 | 0.060 |
Why?
| | Male | 7 | 2025 | 72842 | 0.060 |
Why?
| | Adult | 6 | 2025 | 40777 | 0.060 |
Why?
| | Bolivia | 1 | 2025 | 63 | 0.060 |
Why?
| | Vinca Alkaloids | 1 | 2025 | 6 | 0.060 |
Why?
| | Bridged-Ring Compounds | 1 | 2025 | 31 | 0.060 |
Why?
| | Carnitine | 1 | 2025 | 91 | 0.060 |
Why?
| | Signal Transduction | 1 | 2019 | 5216 | 0.060 |
Why?
| | Taxoids | 1 | 2025 | 114 | 0.050 |
Why?
| | Iran | 1 | 2023 | 44 | 0.050 |
Why?
| | Los Angeles | 1 | 2023 | 73 | 0.050 |
Why?
| | Ion Channels | 1 | 2023 | 129 | 0.050 |
Why?
| | Middle Aged | 4 | 2025 | 36215 | 0.040 |
Why?
| | Chile | 1 | 2021 | 27 | 0.040 |
Why?
| | Colombia | 1 | 2021 | 42 | 0.040 |
Why?
| | Genetic Testing | 1 | 2024 | 480 | 0.040 |
Why?
| | Cesarean Section | 1 | 2023 | 230 | 0.040 |
Why?
| | Adaptation, Physiological | 1 | 2025 | 560 | 0.040 |
Why?
| | Genes, Recessive | 1 | 2021 | 78 | 0.040 |
Why?
| | Mississippi | 1 | 2021 | 28 | 0.040 |
Why?
| | HLA-A Antigens | 1 | 2021 | 52 | 0.040 |
Why?
| | Pharmacogenomic Variants | 1 | 2021 | 35 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2023 | 552 | 0.040 |
Why?
| | Uterine Hemorrhage | 1 | 2021 | 41 | 0.040 |
Why?
| | Drug Implants | 1 | 2021 | 83 | 0.040 |
Why?
| | Mexico | 1 | 2021 | 233 | 0.040 |
Why?
| | Machine Learning | 1 | 2026 | 587 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5904 | 0.040 |
Why?
| | Ultrasonography | 1 | 2024 | 785 | 0.040 |
Why?
| | Risk Factors | 2 | 2025 | 10885 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1997 | 0.040 |
Why?
| | Alleles | 1 | 2022 | 894 | 0.040 |
Why?
| | Phylogeography | 1 | 2019 | 50 | 0.040 |
Why?
| | Genome Size | 1 | 2018 | 9 | 0.040 |
Why?
| | Oxygen | 1 | 2023 | 978 | 0.030 |
Why?
| | Gene Expression | 1 | 2023 | 1476 | 0.030 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2019 | 145 | 0.030 |
Why?
| | Hominidae | 1 | 2019 | 87 | 0.030 |
Why?
| | Birds | 1 | 2018 | 86 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2025 | 3623 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 563 | 0.030 |
Why?
| | DNA Transposable Elements | 1 | 2018 | 124 | 0.030 |
Why?
| | Prevalence | 1 | 2024 | 2865 | 0.030 |
Why?
| | Weight Gain | 1 | 2021 | 561 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2024 | 1149 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2025 | 1196 | 0.030 |
Why?
| | Mammals | 1 | 2018 | 286 | 0.030 |
Why?
| | Self Report | 1 | 2021 | 870 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2021 | 1111 | 0.030 |
Why?
| | Hypoxia | 1 | 2023 | 1199 | 0.030 |
Why?
| | Indians, North American | 1 | 2021 | 597 | 0.030 |
Why?
| | Protein Conformation | 1 | 2019 | 938 | 0.030 |
Why?
| | Cohort Studies | 1 | 2026 | 6013 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2019 | 2129 | 0.030 |
Why?
| | Biological Evolution | 1 | 2019 | 467 | 0.030 |
Why?
| | Young Adult | 2 | 2022 | 14218 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2923 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1598 | 0.020 |
Why?
| | Age Factors | 1 | 2021 | 3342 | 0.020 |
Why?
| | Pandemics | 1 | 2022 | 1707 | 0.020 |
Why?
| | Protein Binding | 1 | 2019 | 2238 | 0.020 |
Why?
| | Prognosis | 1 | 2021 | 4316 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2024 | 8333 | 0.020 |
Why?
| | Risk Assessment | 1 | 2021 | 3747 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 7123 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4295 | 0.020 |
Why?
| | United States | 1 | 2021 | 16098 | 0.010 |
Why?
| | Adolescent | 1 | 2021 | 22529 | 0.010 |
Why?
|
|
Shortt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|